RAC3 is an oncogene naturally overexpressed in several tumors. Besides its role as coactivator, it can exert several protumoral cytoplasmic actions. Autophagy was found to act either as a tumor suppressor during the early stages of tumor development, or as a protector of the tumor cell in later stages under hypoxic conditions. We found that RAC3 overexpression inhibits autophagy when induced by starvation or rapamycin and involves RAC3 nuclear translocation-dependent and -independent mechanisms. Moreover, hypoxia inhibits the RAC3 gene expression leading to the autophagy process, allowing tumor cells to survive until angiogenesis occurs. The interplay between RAC3, hypoxia, and autophagy could be an important mechanism for tumor progression and a good target for a future anticancer therapy. (Cancer Sci 2012; 103: 2064-2071 A utophagy is a highly regulated cellular process that serves to remove damaged proteins and organelles from the cell. It contributes to an array of normal and pathological processes, and has recently emerged as a key regulator of multiple aspects of cancer biology.Autophagy is not only triggered under nutrient deficiency, resulting in mTOR pathway inhibition, but also under cellular stress, or mitochondria or endoplasmic reticulum damage.(1) Several transcription factors can also induce autophagy, such as HIF-a and FoxoA1, which are involved in hypoxia and aging responses, respectively.(1) Autophagy and nuclear factorkappa B (NF-jB) share common signals and regulators; both are able to control each other through positive or negative feedback loops, thus ensuring homeostatic responses.(2) Moreover, kinases were also found to have positive or negative modulation on autophagy. Class I phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) (both involved in the mTOR pathway), p70S6K, and p38 (3) were associated with inhibitory effects, whereas ERK, death-associated protein kinase, and c-Jun N-terminal kinase were involved in positive modulation of autophagy. (4) The molecular mechanism by which autophagy takes place is complex and implicates several steps.(5) Interference at initiation could lead to the complete inhibition of autophagy, and blockage on maturation could result in an abnormal accumulation of immature autophagosomes.(6) In normal cells, these two scenarios could be pathological. However, the role of autophagy in cancer is not at all clear and is likely dependent on tumor type, stage, and genetic context. This complexity is illustrated by the fact that autophagy has a dual effect in tumorigenesis, either inhibiting it during the early stages or promoting it at later stages or during chemotherapy (5) in order to allow tumor maintenance.The gene RAC3 (AIB1, SRC-3, NCoA3) is a member of the nuclear receptor coactivator p160 family, together with SRC-1 and TIF-2.(7,8) Although it was first described as a coactivator of estrogen receptor and other steroid receptors, (8) we have previously found that RAC3 is also a NF-jB coactivator.(9) In any case, it has an intrinsic histone ace...
HighlightsThe inflammatory response increases the expression of RAC3 in vitro and in vivo.TNF induces the increase of RAC3 at transcriptional level through NF-κB activation.Glucocorticoids also induce the increase of RAC3 expression levels.RAC3 appears to be essential for NF-κB- and GR-mediated transcription.
NF-κB regulates the expression of Cyclin D1 (CD1), while RAC3 is an NF-κB coactivator that enhances its transcriptional activity. In this work, we investigated the regulatory role of CD1 on NF-κB activity. We found that CD1 inhibits NF-κB transcriptional activity through a corepressor function that can be reverted by over-expressing RAC3. In both, tumoral and non-tumoral cells, the expression pattern of RAC3 and CD1 is regulated by the cell cycle, showing a gap between the maximal expression levels of each protein. The individual increase, by transfection, of either CD1 or RAC3 enhances cell proliferation. However the simultaneous and constitutive over-expression of both proteins has an inhibitory effect. Our results suggest that the relative amounts of CD1 and RAC3, and the timing of expression of these oncogenes could tilt the balance of tumor cell proliferation in response to external signals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.